Anti-IL-5 for Severe Asthma: Aiming High to Achieve Success

Chest

Volumn 150, Issue 4, 2016, Pages 766-768

  Russell, Richard ^a   Brightling, Christopher E ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENRALIZUMAB; CORTICOSTEROID; DUPILUMAB; FEVIPIPRANT; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; LEBRIKIZUMAB; MEPOLIZUMAB; PLACEBO; RESLIZUMAB; TRALOKINUMAB; TRANSCRIPTION FACTOR RUNX2; ANTIASTHMATIC AGENT; CYTOKINE;

ASTHMA; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; EDITORIAL; EOSINOPHILIA; HUMAN; INNATE IMMUNITY; LUNG FUNCTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SIGNAL TRANSDUCTION; TH2 CELL;

ANTI-ASTHMATIC AGENTS; ASTHMA; CYTOKINES; HUMANS; INTERLEUKIN-5;

EID: 84994524493     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.06.013     Document Type: Editorial

References (12)

1. 1 Chung, K.F., Wenzel, S.E., Brozek, J.L., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43:2 (2014), 343–373.
2. 2 Russell, R., Brightling, C., Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma. Expert Rev Respir Med 10:6 (2016), 607–617.
3. 3 Ortega, H.G., Liu, M.C., Pavord, I.D., et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:13 (2014), 1198–1207.
4. 4 Haldar, P., Brightling, C.E., Hargadon, B., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360:10 (2009), 973–984.
5. 5 Castro, M., Zangrilli, J., Wechsler, M.E., et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3:5 (2015), 355–366.
6. 6 Castro, M., Wenzel, S.E., Bleecker, E.R., et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2:11 (2014), 879–890.
7. 7 Laviolette, M., Gossage, D.L., Gauvreau, G., et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132:5 (2013), 1086–1096.e5.
8. 8 Bjermer, L., Lemiere, C., Maspero, J., Weiss, S., Zangrilli, J., Germinaro, M., Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 150:4 (2016), 789–798.
9. 9 Corren, J., Weinstein, S., Janka, L., Zangrilli, J., Garin, M., Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 150:4 (2016), 799–810.
10. 10 Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies [published online ahead of print May 10, 2016]. Lancet Respir Med. http://dx.doi.org/10.1016/S2213-2600(16)30031-5.
11. 11 Brightling, C.E., Chanez, P., Leigh, R., et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 3:9 (2015), 692–701.
12. 12 Berair, R., Gonem, S., Singapuri, A., et al. Effect of QAW039, an oral prostaglandin D2 receptor (DP2/CRTH2) antagonist, upon sputum and bronchial eosinophilic inflammation and clinical outcomes in treatment-resistant asthma: A phase 2a randomized placebo-controlled trial. Am J. Respir Crit Care Med, 191, 2015, A6361.